{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"VFBNNQOHBYEVLU-UHFFFAOYSA-N","prefName":"NBMEGACLONE","symbol":"CUMYL-BC-HPMEGACLONE-221","iupacName":"5-(2-bicyclo[2.2.1]heptanylmethyl)-2-(2-phenylpropan-2-yl)pyrido[4,3-b]indol-1-one","aliases":["CUMYL-NBMEGACLONE","Cumyl-NBMEGACLONE","Cumyl-BC[2.2.1]HpMeGaClone","CUMYL-NB-MeGACLONE","Cumyl-BC-HPMEGACLONE","SGT-271"],"cas":null,"pubchemCid":"163190698","chebiId":null,"smiles":"CC(C)(c1ccccc1)N1C=Cc2n(CC3CC4CCC3C4)c3ccccc3c2C1=O","molecularFormula":"C28H30N2O","molecularWeight":410.5,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/163190698"}},"classification":{"family":"scra","familyLabel":"Synthetic cannabinoid (SCRA)","origin":"synthetic","originLabel":"Synthétique","structuralClassFr":null},"originSynthesis":{"heading":"Origin (pharmaceutical research → illicit market)","summaryFr":"No known biosynthetic pathway: a chemically synthesised molecule, with no known natural equivalent, belonging to the class of cumylated gamma-carbolinones.","originNote":"Entirely synthetic molecule, absent from the plant. It has been identified in herbal blends onto which it was applied, and belongs to a group of three related compounds carrying a norbornylmethyl substituent (Pulver et al., 2021).","discovered":""},"pharmacology":{"summaryFr":"CUMYL-BC-HPMEGACLONE-221, also called NBMEGACLONE, is a synthetic cannabinoid of the gamma-carbolinone class, bearing a cumyl group and a norbornylmethyl substituent. In the study by Pulver et al. (2023), the six derivatives compared are full CB1 agonists, and the three norbornylmethyl derivatives have affinities between 0.25 and 1.87 nM, although the value specific to this compound is not given in the abstract consulted. Human metabolism was described from 4 authentic urine samples, which yielded 9 phase I metabolites and two markers of consumption (Giorgetti et al., 2025). In the sources consulted, no clinical study, no human toxicology data and no pharmacokinetic data appear. Its French legal status remains evolving: it is not named in the ANSM list, and the generic definition that could cover it does not settle its case.","receptorSummaryFr":"A full agonist at the CB1 receptor. In the study by Pulver et al. (2023), the six derivatives compared, including this compound, are full agonists at CB1 relative to Δ9-THC and CP-55,940. For the three norbornylmethyl derivatives, affinities (Ki) lie between 0.25 and 1.87 nM and functional potencies (EC50) between 1.78 and 169 nM, the indazole derivative being the most affine and tending to be the most potent. The abstract consulted does not give the value specific to this compound. The authors note that this bulky substituent increases the affinity and activity of almost all the core structures tested. No CB2 binding data appear in the sources consulted.","binding":[{"target":"CB1","efficacy":"full_agonist","relativeActivity":93,"reported":"Ki compris entre 0,25 et 1,87 nM pour les trois dérivés norbornylméthyle, valeur propre à ce composé non donnée dans le résumé consulté (Pulver et coll., 2023)","confidence":"medium"}],"references":[{"label":"Pulver et coll., pharmacologie, prévalence en Allemagne et données analytiques des agonistes cannabinoïdes de synthèse à chaîne cyclobutylméthyle et norbornylméthyle, Drug Testing and Analysis, 2023","pmid":"36541839","doi":"10.1002/dta.3427","url":"https://pubmed.ncbi.nlm.nih.gov/36541839/"},{"label":"Giorgetti et coll., métabolisme de phase I humain de trois agonistes cumylés (Cumyl-CBMEGACLONE, Cumyl-NBMEGACLONE, Cumyl-NBMINACA), Drug Testing and Analysis, 2025","pmid":"39218806","doi":"10.1002/dta.3791","url":"https://pubmed.ncbi.nlm.nih.gov/39218806/"},{"label":"Pulver et coll., jeu de données spectrales pour l'identification de trois cannabimimétiques de synthèse à chaîne norbornylméthyle, Data in Brief, 2021","pmid":"34988267","doi":"10.1016/j.dib.2021.107628","url":"https://pubmed.ncbi.nlm.nih.gov/34988267/"},{"label":"ANSM, Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"INCB, Green List 2026 (substances des tableaux de la Convention de 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"},{"label":"PubChem, CID 163190698","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/163190698"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calm","description":"Relaxation of body and mind; reduced mental noise without marked drowsiness.","intensity":12},{"key":"focus","label":"Clarity","description":"Sustained attention and clear thinking; functional lucidity, not euphoria.","intensity":5},{"key":"sleep","label":"Sleep","description":"Sedative effect: aids sleep onset and the continuity of deep sleep.","intensity":12},{"key":"appetite","label":"Appetite","description":"Stimulation of hunger and of taste appreciation (the “munchies” effect).","intensity":20},{"key":"uplift","label":"High","description":"Euphoria and sensory intensity; altered perception of time and space.","intensity":18}],"doseRanges":null,"humanDataCharacterised":false},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":true,"bannerTextFr":"Aucune dose humaine caractérisée : données animales / in vitro uniquement. Profil d'effet, marge de sécurité et toxicité aiguë non documentés en clinique humaine.","toxicologyFr":null},"legal":{"scheduleStatus":"unscheduled","scheduleLabel":"Unscheduled","frScheduleStatus":"evolving","tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"No harmonised European Union control measure was found for this molecule in the sources consulted. It does not appear in the schedules of the 1971 Convention as reproduced in the INCB Green List 2026. Control therefore falls under the national legislation of the Member States, which are not detailed here.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"This compound is not named in the consolidated list of substances classed as narcotics published by ANSM, updated 16 February 2026. The generic text covering “3-carboxamide indole derivatives” could apply to it: the nitrogen of the carboxamide bridge is part of a ring, a condition met here. However, the condition on the substituent of the indole nitrogen, “cycloalkylmethyl” or equivalent, is not settled by the text for a bridged bicyclic substituent such as norbornylmethyl. As this cannot be decided with certainty, the status is treated as evolving. The neighbouring compound CUMYL-CH-MEGACLONE, with a cyclohexylmethyl ring, is by contrast named by a decision of 22 May 2024.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Pulver et coll., pharmacologie, prévalence en Allemagne et données analytiques des agonistes cannabinoïdes de synthèse à chaîne cyclobutylméthyle et norbornylméthyle, Drug Testing and Analysis, 2023","pmid":"36541839","doi":"10.1002/dta.3427","url":"https://pubmed.ncbi.nlm.nih.gov/36541839/"},{"label":"Giorgetti et coll., métabolisme de phase I humain de trois agonistes cumylés (Cumyl-CBMEGACLONE, Cumyl-NBMEGACLONE, Cumyl-NBMINACA), Drug Testing and Analysis, 2025","pmid":"39218806","doi":"10.1002/dta.3791","url":"https://pubmed.ncbi.nlm.nih.gov/39218806/"},{"label":"Pulver et coll., jeu de données spectrales pour l'identification de trois cannabimimétiques de synthèse à chaîne norbornylméthyle, Data in Brief, 2021","pmid":"34988267","doi":"10.1016/j.dib.2021.107628","url":"https://pubmed.ncbi.nlm.nih.gov/34988267/"},{"label":"ANSM, Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"INCB, Green List 2026 (substances des tableaux de la Convention de 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"},{"label":"PubChem, CID 163190698","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/163190698"}],"meta":{"slug":"cumyl-bc-hpmegaclone-221","url":"https://en.phytogrammes.com/wiki/cumyl-bc-hpmegaclone-221","lastVerified":"2026-05-01","dataUpdatedAt":"2026-10-13","confidence":"high","dataCompletenessPct":90,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}